Here you can find studies currently accepting participants in Australia.
Click on the study names for more information. If you are interested in participating in a study, please contact that study directly.
Are you interested in future research projects? Join our email list and we will send you an email as soon as a new study is added to this page.
|Study Name||Study Focus||Study Aim||State(s)||Who can participate?||Allergy Status|
|PEBBLES||Prevention||To find out if infant skin management with a particular cream, called EpiCeram™, might help reduce the chances that a child will develop allergies||VIC||Infants, aged 0-3 weeks (expressions of interest from pregnant women welcome)||Baby to have family history of allergy|
|OPTIMUM||Prevention||To investigate if giving a dose of 'whole-cell' whooping cough vaccine between 6 and 12 weeks of age, instead of the 'acellular' whooping cough vaccine can help protect against allergy||WA||Infants, aged 6-12 weeks||All welcome|
|OPIA||Treatment||To determine whether graded peanut ingestion along with a dietary fibre supplement can train the body to become tolerant to peanut in children with peanut allergy||ACT, NSW||Children/Adolescents, aged 10-16 years||Food allergy – peanut|
|VITALITY||Prevention||To assess whether vitamin D supplementation during infancy can prevent food allergy in the first year of life||VIC||Infants, aged 6-12 weeks||All welcome|
|SYMBA||Prevention||To determine whether maternal prebiotic supplementation during pregnancy and breastfeeding can reduce the development of eczema in babies||WA||Pregnant women, less than 21 weeks gestation||Baby to have family history of allergy|
|PrEggNut||Prevention||To test whether the amount of eggs and peanuts a mother eats during pregnancy and breastfeeding has an influence on her baby’s food allergy development||Now: WA, SA|
Planned: NSW, VIC
|Pregnant women, less than 23 weeks gestation||Baby to have family history of allergy|
|PEAT||Treatment||To test the hypothesis that probiotic and egg OIT is more effective than placebo at inducing sustained unresponsiveness (remission) in participants with egg allergy 8 weeks after end-of-treatment||VIC||Children/Adolescents, aged 5-17 years||Food allergy – egg|
|EPITOPE||Treatment||To evaluate the safety and efficacy of a novel desensitisation method, called EPicutaneous ImmunoTherapy (EPIT) with the Viaskin® Peanut patch in young children||Now: NSW - Westmead, QLD, SA, VIC, WA|
Planned: NSW - Randwick
|Children, aged 1-3 years||Food allergy – peanut|
Last modified: July 30th 2019 | Date created: May 28th 2019